These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
220 related articles for article (PubMed ID: 10496304)
21. Application of preformed hammerhead ribozymes in the gene therapy of cancer (review). Sioud M Int J Mol Med; 1999 Apr; 3(4):381-4. PubMed ID: 10085409 [TBL] [Abstract][Full Text] [Related]
22. Gene-expressed RNA as a therapeutic: issues to consider, using ribozymes and small hairpin RNA as specific examples. Fanning GC; Symonds G Handb Exp Pharmacol; 2006; (173):289-303. PubMed ID: 16594621 [TBL] [Abstract][Full Text] [Related]
23. Antisense makes sense in engineered regenerative medicine. Yao Y; Wang C; Varshney RR; Wang DA Pharm Res; 2009 Feb; 26(2):263-75. PubMed ID: 19015958 [TBL] [Abstract][Full Text] [Related]
24. Antisense approaches to cancer gene therapy. Mercola D; Cohen JS Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254 [TBL] [Abstract][Full Text] [Related]
32. Progress and Prospects of Anti-HBV Gene Therapy Development. Maepa MB; Roelofse I; Ely A; Arbuthnot P Int J Mol Sci; 2015 Jul; 16(8):17589-610. PubMed ID: 26263978 [TBL] [Abstract][Full Text] [Related]
33. Ribozyme and peptide-nucleic acid-based gene therapy. Phylactou LA Adv Drug Deliv Rev; 2000 Nov; 44(2-3):97-108. PubMed ID: 11072108 [TBL] [Abstract][Full Text] [Related]
34. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design. Tabler M; Homann M; Tzortzakaki S; Sczakiel G Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118 [TBL] [Abstract][Full Text] [Related]
35. Cellular uptake properties of a 2'-amino/2'-O-methyl-modified chimeric hammerhead ribozyme targeted to the epidermal growth factor receptor mRNA. Fell PL; Hudson AJ; Reynolds MA; Usman N; Akhtar S Antisense Nucleic Acid Drug Dev; 1997 Aug; 7(4):319-26. PubMed ID: 9303183 [TBL] [Abstract][Full Text] [Related]
38. Nucleic-acid therapeutics: basic principles and recent applications. Opalinska JB; Gewirtz AM Nat Rev Drug Discov; 2002 Jul; 1(7):503-14. PubMed ID: 12120257 [TBL] [Abstract][Full Text] [Related]
39. Antisense technologies have a future fighting neurodegenerative diseases. Seidman S; Eckstein F; Grifman M; Soreq H Antisense Nucleic Acid Drug Dev; 1999 Aug; 9(4):333-40. PubMed ID: 10463077 [TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cucco C; Calabretta B Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]